[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628893":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":20,"responsibleParty":84,"collaborators":86,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":7,"enrollmentInfo":99,"targetDuration":7,"studyType":102,"phases":7,"briefSummary":103,"conditions":104,"keywords":7,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Sanofi","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Dupilumab","This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.",[14],{"name":15,"role":16,"phone":17,"phoneExt":18,"email":19},"Trial Transparency email recommended (Toll free for US & Canada)","CONTACT","800-633-1610","option 6","Contact-US@sanofi.com",[21,33,45,50,60,68,76],{"facility":22,"status":23,"city":24,"state":7,"zip":7,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":7},"Investigational Site: Hamad Medical Corporation","ACTIVE_NOT_RECRUITING","Doha","Qatar","QA",{"type":28,"coordinates":29},"Point",[30,31],51.53096,25.28545,{"lat":31,"lon":30},{"facility":34,"status":35,"city":36,"state":7,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":44,"contacts":7},"Investigational Site: Saudi Medical Services (Medical Fakeeh)","RECRUITING","Jeddah","21331","Saudi Arabia","SA",{"type":28,"coordinates":41},[42,43],39.18624,21.49012,{"lat":43,"lon":42},{"facility":46,"status":23,"city":36,"state":7,"zip":7,"country":38,"countryCode":39,"cosmosGeoPoint":47,"geoPoint":49,"contacts":7},"Investigational Site: King Faisal Specialist Hospital",{"type":28,"coordinates":48},[42,43],{"lat":43,"lon":42},{"facility":51,"status":35,"city":52,"state":7,"zip":7,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":59,"contacts":7},"Investigational Site: NMC Specialty Hospital LTD","Abu Dhabi","United Arab Emirates","AE",{"type":28,"coordinates":56},[57,58],54.39696,24.45118,{"lat":58,"lon":57},{"facility":61,"status":35,"city":62,"state":7,"zip":7,"country":53,"countryCode":54,"cosmosGeoPoint":63,"geoPoint":67,"contacts":7},"Investigational Site: Dibba Hospital","Fujairah",{"type":28,"coordinates":64},[65,66],56.34141,25.11641,{"lat":66,"lon":65},{"facility":69,"status":35,"city":70,"state":7,"zip":7,"country":53,"countryCode":54,"cosmosGeoPoint":71,"geoPoint":75,"contacts":7},"Investigational Site: Ibrahem Bin Hamad Hospital","Ras al-Khaimah",{"type":28,"coordinates":72},[73,74],55.9432,25.78953,{"lat":74,"lon":73},{"facility":77,"status":23,"city":78,"state":7,"zip":7,"country":53,"countryCode":54,"cosmosGeoPoint":79,"geoPoint":83,"contacts":7},"Investigational Site: Al Qassimi Hospital","Sharjah city",{"type":28,"coordinates":80},[81,82],55.41221,25.3342,{"lat":82,"lon":81},{"type":85,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[87],{"name":88,"class":6},"Regeneron Pharmaceuticals","100628893","the-impact-of-dupilumab-treatment-on-anxiety-and-depression-symptoms-in-patients-with-moderate-to-severe-atopic-dermatitis-100628893",false,"NCT07467564","The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis","The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries","DERMIND-AD","Inclusion Criteria:\n\n* Participants who have moderate to severe AD with signs and symptoms of anxiety and\u002For depression.\n* Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation\n* Participants and\u002For their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent.\n\nExclusion Criteria:\n\n* Females who are pregnant, lactating, or planning\u002Fintending to be pregnant in the next 6 months.\n* Participants who are participating in another trial.\n* Participants with active chronic or acute infection requiring systemic treatment.\n* Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection.\n* Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses.\n* Participants on antidepressants\u002Fanti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants\u002Fanti-anxiety. In addition, those who will use antidepressants\u002Fanti-anxiety medications throughout the study will be excluded from the analysis.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","ALL","12 Years",{"count":100,"type":101},184,"ESTIMATED","OBSERVATIONAL","This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.",[105],"Atopic Dermatitis","2026-07-27",{"date":108,"type":109},"2026-07-28","ACTUAL",{"date":111,"type":109},"2026-02-24",{"date":113,"type":101},"2027-05-24",{"name":5,"class":6},7]